TrialPRGN-2009 in Combination With Pembrolizumab in Patients With Recurrent or Metastatic Cervical Cancer
Trial details
- Registry ID
- NCT06157151
- Phase
- Phase 2
PGEN
Precigen, Inc
Company identity checked against sources
Browse linked trials and recorded changes, or follow this company for updates.
1Trials in this database
3Recorded changes · last 12 months
Partial coverageOnly the trials and history collected so far
Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.
Completion dates · Pro
Which trial dates moved later?
Pro summarizes how far estimated completion dates moved later and counts trials with edits to their main study measures, using the history available here. View Pro features
Included trials
Check company identity source| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| PRGN-2009 in Combination With Pembrolizumab in Patients With Recurrent or Metastatic Cervical CancerNCT06157151 | PGEN | Phase 2 | Recruiting | 2026-11-11Estimated |
Latest recorded trial changes
PRGN-2009 in Combination With Pembrolizumab in Patients With Recurrent or Metastatic Cervical Cancer
NCT06157151 · Precigen, Inc
Main study measure wording changed
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Compare wording
− Before
Measure: Determine the Objective Response Rate (ORR) following treatment with PRGN-2009 in combination with pembrolizumab or pembrolizumab alone in patients with pembrolizumab-resistant recurrent or metastatic cervical cancer.
+ After
Measure: Determine the Objective Response Rate (ORR) following treatment with PRGN-2009 in combination with pembrolizumab in patients with pembrolizumab-resistant recurrent or metastatic cervical cancer.
Planned enrollment decreased by 22 participants
− Before
46 participants (planned)
+ After
24 participants (planned)
Primary completion date changed
− Before
30 Jan 2028
+ After
11 Nov 2026